Serotonin 5-HT1A Agonists: A Comparative Review

CNS Drugs

Volumn 2, Issue 3, 1994, Pages 234-251

  Pecknold, John C ^a  

^a DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000986365     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/00023210-199402030-00007     Document Type: Review

References (206)

1. The involvement of serotonin in psychiatric disorders and behaviour
2. Some neurophysiological aspects to serotonin
3. Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidiol
4. An overview of 5-hydroxytryptamine receptor families
5. Psychoactive agents. 2,8-(4-substituted 1-piperazinylalkyl)-8-azospiro (4.5 decane-7,9-diones
6. Inhibition of aggressive behaviour in rhesus monkeys by buspirone
7. 3H-5-hydroxytryptamine binding sites by the neuroleptic spiperone in rat brain
8. 8-hydroxy-2-(di-n-propylamino)tetralin, a new centrally acting 5-hydroxytryptamine receptor agonist
9. 3H-8-OH-DPAT
10. Buspirone. Action on serotonin receptors in calf hippocampus
11. Binding of the putative anxiolytic TVX Q 7821 to hippocampal 5-hydroxytryptamine (5-HT) recognition sites
12. 1 binding sites as target for a novel putative anxiolytic
13. Biochemical evidence for the 5-HT agonist properties of PAT [8-hydroxy-2-(di-n-propylamino)tetralin] in the rat brain
14. 1A receptor partial agonists as anxiolytics
15. 1A receptors in anxiety
16. 1A binding sites with G regulatory proteins
17. 1A receptor
18. 3H]8-methoxy-3’-NAP-amino-PAT
19. 1 receptors
20. The role of G proteins in transmembrane signalling
21. 1A agonists
22. 1A subtype
23. Electrophysiologically-identified serotonin receptors in the rat CNS
24. 1A binding sites on serotonin containing neurons in the raphe dorsalis and raphe centralis nuclei of the rat brain
25. 1B agonists
26. 1A selective agonists
27. Ipsapirone depresses neuronal activity in the dorsal raphe nucleus and the hippocampal formation
28. 1A-Rezeptoren als Angriffspunkt für neuartige Anxiolytika. Biochemische und verhaltenspharmakologische Aspekte
29. 1A receptor functions
30. Inhibition of serotonergic dorsal raphe neurons by systemic and iontophoretic administration of buspirone, a non-benzodiazepine anxiolytic drug
31. 1A receptors
32. 1A receptor mediated inhibition of forskolin-stimulated adenylate cyclase activity in guinea pig and rat hippocampal membranes
33. Pharmacology of 5-hydroxytryptamine-1A receptors which inhibit cAMP production in hippocampal and cortical neurons in primary culture
34. 1A binding sites inhibit forskolin-stimulated adenylate cyclase activity in calf hippocampus
35. Serotonin: a common neurobiologic substitute in anxiety and depression
36. 1A agonist gepirone: electrophysiological studies in the rat brain
37. 1A agonist flesinoxan on the 5-HT system: electrophysiological studies in the rat CNS [abstract]
38. Tandospirone and its metabolite, 1-(2-pyrimidinyl)piperazine (1-PP): I. Effects of acute and long-term tandospirone on serotonin neuro-transmission
39. 1A receptors in rat brain following antidepressant drug treatment
40. Effects of acute and chronic administration of buspirone on serotonin and benzodiazepine receptor subtypes in the rat brain: an autoradiographic study
41. 1A receptor binding sites following subchronic treatment with ipsapirone [abstract]
42. Alterations of central serotonergic and dopaminergic neurotransmission in rats chronically treated with ipsapirone: biochemical and electrophysiological studies
43. Preclinical profile of the pyrimidinylpiperazinyl imide compound WY-47,846: a potential anxiolytic
44. Reduction in cortical 5-HT2 receptor sensitivity after continuous gepirone treatment
45. Modulations of central serotonergic neurotransmission by chronic ipsapirone in the rat
46. Alpha2-adrenoceptor antagonist activity may account for the effects of buspirone in an anti-conflict test in the rat
47. 1A receptor linked to adenylate cyclase in rat and guinea pig hippocampal preparations [abstract
48. Pharmacocinetique de la buspirone
49. 1A agonists: animal models of anxiety and depression
50. Inhibition of aggressive behavior in rhesus monkeys by buspirone
51. Relationship between benzodiazepine receptors and experimental anxiety in rats
52. A simple and reliable conflict procedure for testing anti-anxiety agents
53. Serotonergic mechanisms in the behavioral effects of buspirone and gepirone
54. Animal models of anxiety: the effect of compounds that modify 5-HT neurotransmissions
55. The neurochemistry of anxiety
56. Pharmacological characterization of a modified social interaction model of anxiety in the rat
57. Selective agonists and antagonists for 5-hydroxytryptamine receptor subtypes and interactions with yohimbine and FG 7142 using the elevated plus-maze in the rat
58. 1A receptor agonists and L-5-HTP in Montgomery’s conflict test
59. 1A receptor agonists in the social interaction test and the elevated plus maze
60. 1A partial agonist ipsapirone on socio-physiologically induced stomach lesion of mice
61. Ultrasonic vocalization by rat pups as an animal model for anxiolytic activity [abstract
62. Comparison of buspirone in two separate studies
63. Buspirone: anxiolytic?
64. Buspirone and diazepam in anxiety: a controlled study
65. A double-blind comparison of buspirone and diazepam in outpatients with generalized anxiety disorder
66. 1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression
67. Evaluation of buspirone as an antianxiety agent: buspirone and diazepam versus placebo
68. Buspirone therapy in anxious elderly patients: a controlled clinical trial
69. A pooled, double-blind comparison of the effects of buspirone, diazepam and placebo in women with chronic anxiety
70. Comparative assessment of efficacy and withdrawal symptoms after 6 and 12 weeks treatment with diazepam or buspirone
71. The clinical course and long-term management of generalized anxiety disorder
72. Buspirone in the long term management of generalized anxiety disorder
73. Long-term buspirone therapy for chronic anxiety: a multicenter international study to determine safety
74. Gepirone in anxiety: a pilot study
75. Clinical profile of gepirone: a non-benzodiazepine anxiolytic
76. Promising anxiolytics? A new class of drugs: the azapirones
77. The safety and efficacy of ipsapirone vs lorazepam in outpatients with generalized anxiety disorder (GAD): single site findings from a multicenter trial
78. Long-term treatment of anxiety and risk of withdrawal. Prospective comparison of clorazepate and buspirone
79. A comparison of buspirone, diazepam and placebo in patients with chronic anxiety states
80. Potential antidepressant properties of 8-hydroxy-2(di-n-propylamine)tetraline, a selective serotonin receptor agonist
81. Different effects of intracerebral and systemic administration of buspirone in the forced swim test: involvement of a metabolite
82. 1A agonists
83. Buspirone attenuates learned helplessness behavior in rats
84. 1A agonists and conventional antidepressants in an animal model of depression
85. The antidepressant effect of buspirone and its analogue, gepirone
86. The comparative efficacy of buspirone and diazepam in the treatment of anxiety
87. Open trial of buspirone in the treatment of major depressive disorder
88. Open trial of gepirone in the treatment of major depressive disorder
89. 1A agonist in the treatment of major depression
90. Gepirone in the treatment of major depression
91. Ipsapirone: evidence for efficacy in depression
92. The role of serotonin in anxiety: behavioural approaches
93. Benzodiazepines: anxiety-reducing activity by reduction of serotonin turnover in the brain
94. Comparison of the effects of benzodiazepines and other anticonvulsant drugs on synthesis and utilization of 5-HT in mouse brain
95. The effects of benzodiazepines and serotonergic manipulations on punished responding
96. Anticonflict effect of the putative serotonin receptor agonist 8-hydroxy-2(di-n-propylamino)tetraline (8-OH-DPAT
97. Tryptaminergic mechanisms in punished and non-punished behavior
98. Behavioral pharmacology of anxiety drugs
99. Serotonin receptors and the mechanism of action of antidepressant drugs: postmortem, platelet, and neuroendocrine studies in depressed patients
100. A pooled, double-blind comparison of the effects of buspirone, diazepam and placebo in women with chronic anxiety
101. 1A receptor agonists
102. Modulations of central serotonergic neurotransmission by chronic ipsapirone in the rat
103. Preclinical profile of the pyrimidinylpiperazinyl imide compound WY-47,846: a potential anxiolytic
104. Reduction in cortical 5-HT2 receptor sensitivity after continuous gepirone treatment
105. Lactate-induced panic attacks: possible involvement of serotonin reuptake stimulation
106. Serotonin uptake in panic disorder and agoraphobia
107. Treatment of panic disorder: use of nonbenzodiazepine anxiolytics, including buspirone
108. Serotonergic anxiolytics in the treatment of panic disorder: a controlled study with buspirone
109. The relative efficacy of buspirone, imipramine and placebo in panic disorder: a preliminary report
110. Is buspirone effective for panic disorder?
111. The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study
112. Gepirone and the treatment of panic disorder: an open study
113. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment
114. Drug treatment of panic disorder: comparative efficacy of alprazolam, imipramine and placebo
115. NJ 13805-1 — potential nonbenzodiazepine
116. 1A receptor linked to adenylate cyclase in rat and guinea pig hippocampal preparations [abstract
117. Serotonin receptors involved in the interaction with excitatory amino acids in the nucleus locus ceruleus of the rat
118. 1A receptors to selectively attenuate glutamate-evoked responses of locus ceruleus neurons [abstract
119. Clomipramine treatment of obsessive compulsive disorder. I. A controlled clinical trial
120. The Yale-Brown Obsessive Compulsive Scale. II. Validity
121. Results of a double-blind placebo controlled trial using a new serotonin uptake inhibitor sertraline in obsessive compulsive disorder
122. Clomipramine treatment of childhood obsessive-compulsive disorder: a double-blind controlled study
123. Serotonergic responsivity in obsessive compulsive disorder: a comparison of patients and healthy controls
124. 1A receptors in obsessive compulsive disorder
125. Buspirone in obsessive compulsive disorder. [letter]
126. An open trial of buspirone in obsessive-compulsive disorder
127. Buspirone augmentation in patients with obsessive compulsive disorder
128. Buspirone augmentation of fluoxetine in obsessive-compulsive disorder
129. Controlled comparison of buspirone and clomipramine in obsessive-compulsive disorder
130. Selective effects of buspirone and molindone on dopamine metabolism and function in the striatum and frontal cortex of the rat
131. Buspirone as a midbrain modulator: anxiolysis unrelated to traditional benzodiazepine mechanisms
132. Dopamine receptor antagonism by the novel anti-anxiety drug, buspirone
133. Pharmacology and neurology of buspirone
134. Changing concepts of the biochemical action of the anxioselective drug, buspirone
135. Dopaminergic effects of buspirone, a novel anxiolytic agent
136. Comparative chronic effects of buspirone or neuroleptics on rat brain dopaminergic neurotransmission
137. Azapirones: clinical uses of serotonin partial agonists
138. High dose buspirone in case of tardive dyskinesia [correspondence
139. Effects of buspirone in severe schizophrenic subjects
140. Buspirone suppression of neuroleptic-induced akathisia: multiple case reports
141. Clinical effect of buspirone on autistic children
142. The interrelationship of anxiety and alcoholism: a serotonin hypothesis
143. Genetics of ethanol preference: role of neurotransmitters
144. Alterations in brain monoamine oxidase kinetics after chronic alcohol administration and withdrawal
145. Chronic ethanol inhibits rat hippocampal stimulus-secretion coupling mechanism for 5-hydroxytryptamine in vitro
146. Experimental studies on alcoholism. I. Increase in alcohol preference by 5,6-dihydroxytryptamine and brain acetylcholine
147. Brain monoamines and free choice ethanol consumption in rats
148. Buspirone alters alcohol drinking induced in rats by tetrahydropapaveroline injected into brain monoaminergic pathways
149. Contents of monoamines in forebrain regions of alcohol-preferring (P) and non-preferring (NP) lines of rats
150. Higher density of serotonin-1A receptors in the hippocampus and cerebral cortex of alcohol-preferring P rats
151. Factors influencing monoamine metabolites and tryptophan in patients with alcohol dependence
152. Blood platelet uptake of serotonin in men alcoholics
153. Platelet uptake of serotonin (5-HT) during ethanol withdrawal in male alcoholics
154. Altered conversion of tryptophan to kynurenine in newly abstinent alcoholics
155. Alcohol and central serotonin metabolism in man
156. Abuse potential of buspirone and related drugs
157. Assessment of the abuse liability of buspirone in recreational sedative users
158. Investigation of the abuse liability of buspirone in alcohol-dependent patients
159. 1A receptors
160. Effects of buspirone and diazepam, alone and in combination with alcohol on skilled performance and evoked potentials
161. Effects of alcohol on buspirone and lorazepam action
162. Anxiolytics and the alcoholic patient
163. Buspirone in the treatment of alcoholic patients
164. A placebo controlled trial of buspirone in anxious inpatient alcoholics
165. Treatment of comorbid generalized anxiety in a recently detoxified alcohol population with selective serotonergic drug (buspirone
166. Anxiety disorders coexisting with substance dependence: treatment with buspirone
167. Basal ganglia/limbic striatal and thalamocortico involvement in craving and loss of control in alcoholism
168. Buspirone reduces smoking
169. Anxiolytic response to buspirone in chronic cocaine and phencyclidine abusers
170. Buspirone hydrochloride in the treatment of transvestite fetishism
171. Pharmacokinetics of the azapirones
172. Pharmacokinetics and disposition of 14-C-Buspirone HCl after intravenous and oral dosing in man
173. Metabolic fate of 14-C/15-N-Buspirone in man
174. The relationship between buspirone bioavailability and dose in healthy subjects
175. Metabolism of the antianxiety drug buspirone in human subjects
176. Ipsapirone hydrochloride: pharmacokinetics in man
177. Dose-response relationship in Phase I study of BAY q7821 (ipsapirone)
178. Effect of food on the bioavailability of gepirone in humans
179. 14C-gepirone [abstract]
180. Pharmacokinetics of buspirone in elderly subjects
181. Clinical pharmacokinetics of oral buspirone in patients with impaired renal function
182. Buspirone pharmacokinetics in patients with cirrhosis
183. The effects of buspirone binding to the binding of digoxin, Dilantin, propranolol and warfarin to human plasma
184. Metabolism and disposition of buspirone
185. Lack of interaction between cimetidine and buspirone
186. 1A agonists
187. 1-Arylpiperazines as active metabolites of (4-substituted aryl-1-piperazinyl) akyl heterocyclic drugs
188. Evaluation of the safety and side effects of antianxiety agents
189. The safety and usefulness of buspirone as an anxiolytic drug in elderly versus young patients
190. An open study of buspirone in octogenarians with anxiety
191. Buspirone, an anxiolytic drug that stimulates respiration
192. Buspirone administration to sleep apnea patients [correspondence
193. Effects of long term administration of buspirone and diazepam on driver steering control
194. Effects of chronically administered buspirone and diazepam on driving-related skills performance
195. Combined effects of buspirone and diazepam on objective and subjective tests of performance in healthy volunteers
196. Buspirone and diazepam: comparison of subjective, psychomotor and biological effects
197. Repeated dose effects of buspirone and clobazam on cognitive and psychomotor performance
198. Effects of acute doses of buspirone and clobazam on cognitive and psychomotor performance
199. New vistas for serotonin 1A agonists in psychiatry